Skip to main content
Experimental & Molecular Medicine logoLink to Experimental & Molecular Medicine
. 2018 Jul 27;50(7):1–11. doi: 10.1038/s12276-018-0105-2

N-α-acetyltransferase 10 (NAA10) in development: the role of NAA10

Mi-Ni Lee 1,#, Hyae Yon Kweon 1,#, Goo Taeg Oh 1,
PMCID: PMC6063908  PMID: 30054454

Abstract

N-α-acetyltransferase 10 (NAA10) is a subunit of Nα-terminal protein acetyltransferase that plays a role in many biological processes. Among the six N-α-acetyltransferases (NATs) in eukaryotes, the biological significance of the N-terminal acetyl-activity of Naa10 has been the most studied. Recent findings in a few species, including humans, indicate that loss of N-terminal acetylation by NAA10 is associated with developmental defects. However, very little is known about the role of NAA10, and more research is required in relation to the developmental process. This review summarizes recent studies to understand the function of NAA10 in the development of multicellular organisms.

Subject terms: Protein folding, Protein folding

Developmental disorders: Focus on enzyme activity

Further investigations are needed into the role of a key enzyme in biological development and its encoding gene. The enzyme N-α-acetyltransferase 10 (NAA10), encoded by the NAA10 gene, plays a role in multiple biological processes. While the function of NAA10 has been studied in cancer, less is known about the roles of the gene and the enzyme during development, according to a review by Goo Taeg Oh and co-workers at the Ewha Womans University in Seoul, South Korea. Mutations in NAA10 are found in patients with developmental delay, cardiac problems and skeletal abnormalities, while reduced enzyme activity is associated with developmental defects. Mouse studies suggest a role for NAA10 in neuronal development, bone formation and healthy sperm generation. The impact of variable NAA10 expression in different organs at different developmental stages needs clarification.

Introduction

N-α-acetyltransferase 10 (NAA10), the catalytic subunit of N-acetyltransferase A (NatA), a major N-terminal acetyltransferase complex, catalyzes the alpha (N-terminal) acetylation of nascent peptides as a cotranslational modification and epsilon (internal) acetylation of mature proteins (including itself) as a posttranslational modification14. NAA10, which is conserved from yeast to humans and expressed in most cell types, is an important regulator in diverse biological processes, such as cell growth, differentiation, metastasis, apoptosis, and autophagy410. In mammalian cells, most studies about the function of NAA10 are mainly focused on its relationship with cancer. Meanwhile, the biological significance of NAA10 is not as well understood, and further studies are needed in the context of a developing multicellular organism. Recently, NAA10 has been reported to play a critical role in development and human genetic diseases1116. According to these reports, several human genetic diseases have been shown to be associated with NAA10 mutations, thus highlighting the importance of NAA10 function during biological development. In this review, we mainly focus on NAA10 function during the development of multicellular organisms.

Expression of NAA10 during embryonic development

NAA10 is located on chromosome Xq28 in humans and X A7.3 in mouse, and is encoded by 8 exons17,18. Alternative splicing of its mRNA produces several isoforms of NAA10. There are three mouse variants (mNaa10198, mNaa10225, and mNaa10235) and two human variants (hNaa10131 and hNaa10235). The mNaa10225, mNaa10235, and hNaa10235 are the functional isoforms that contain the full N-acetyltransferase domain sequence, and they have been the most extensively studied and characterized among the aforementioned variants1820. Additionally, a homologous gene of NAA10, termed NAA11, has been identified. The human NAA11 is located on chromosome 4q21.23, and the sequence of hNAA11 protein is 81% identical to hNAA10, whereas mouse Naa11 is on chromosome 5E321.

Previous studies showed the broad and ubiquitous expression of NAA10 in various cell types, including tumor cell lines and several tissue types, in the developmental stages of embryos and in adults. In general, dynamic changes in the spatiotemporal expression of distinct genes are shown during embryogenesis22. The regulation of tissue- and stage-specific expression affects the development of different organs individually23. On the basis of this information, it is reasonable to suggest that the potential role of NAA10 varies depending on transcriptional levels in different tissues and embryonic stages during development. Interestingly, in mouse, according to expression atlas databases, the RNA expression level of mNaa10 for each organ is higher in the developmental stages of embryo than in the neonate24,25. For example, in kidney, liver and lung, the RNA level of mNaa10, which is very high in the stage from E12 to E14, decreased to half of this level in the neonate (Fig. 1a). A broad comparison of RNA levels between fetus and adult in humans indicated the same results as those found for mouse2427 (Fig. 1b). However, there are other instances in which an increased or steady expression level is shown in some tissues at the postnatal stage, so we cannot form a definitive conclusion. Whether the changes in tissue- and stage-specific expression have an impact on development needs further investigation.

Fig. 1.

Fig. 1

Tissue-specific expression of Naa10 during different developmental stages in C57BL6/J mouse (a) and in humans (b). Different patterns of expression are observed in each tissue depending on the developmental stage. For the analysis of expression, transcriptome data were extracted from the FANTOM5 Project. TPM transcripts per kilobase million

N-terminal acetylation dependent functions of NAA10 during embryonic development

Acetylation is one of the protein modifications that diversifies the function of genes in organisms. In particular, N-terminal acetylation occurs in 80~90% of eukaryotic proteins, and the molecular role of N-terminal acetylation affects various protein functions, including protein interaction, localization to the ER and degradation. To date, six distinct forms of NATs (NatA – NatF) have been identified in eukaryotes, and they are classified based on different subunit compositions28,29. Among others, NatA undertakes the majority of N-terminal acetylation, acetylating ~40% of the human proteome10,2831. However, the distinct function of NatA has not yet been demonstrated during embryonic development. Nonetheless, abnormal phenotypes were observed in several species due to the absence or reduction of NAA10. These data are of great interest for understanding the role of NAA10 in development.

Developmental roles in humans

Recently, the importance of NAA10 catalytic activity in human development has emerged through the discovery of various NAA10 mutations in several pathological conditions (Table 1). Rope et al. reported the first human genetic disorder caused by a Ser37Pro mutation in NAA10 and termed the lethal X-linked Ogden syndrome14,32. Since this discovery, more human genetic disorders caused by NAA10 missense mutations, including Tyr43Ser, Arg83Cys, Phe128Leu/Ile, Val107Phe, and Arg116Trp, have been discovered11,13,15,16. Among a wide spectrum of malformations in NAA10-related syndromes, there are some common phenotypes with global developmental delay, cardiac anomalies, and intellectual disabilities, and the corresponding NAA10 mutations triggered a reduction in catalytic activity, suggesting that NATs are essential during early embryogenesis and that they possess important regulatory functions during tissue and organ development11,33.

Table 1.

Summary of phenotypes in human NAA10 mutations

Organism scientific name Homolog Type of mutation Protein effect/molecular mechanism Phenotype Ref.
Human Homo sapiens NAA10 Ser37Pro Impaired Nt-acetylation in vivo using COFRADIC, reduced catalytic activity for EEEI, DDDI, and SESS, inability to combine with Naa15, reduced degree of Nt-acetylation of THOC7 Perinatal lethal disorder, hypotonia, global developmental delay, cryptorchidism, cardiac arrhythmias, skin laxity, dysmorphic features, hernias, large fontanels 32
c.471+2T→A STRA6 expression significantly decreased, loss of TSC2 binding and a reduction of TSC2 stability Eye malformations, mild to severe developmental delay, defects in the skeletal and genitourinary systems, congenital bilateral anophthalmia, postnatal growth failure, skeletal anomalies, hypotonia, moderate-to-severe mental retardation 12
Tyr43Ser Catalytically impaired in vitro, with approximately an 85% reduction in Nt-catalytic activity for EEEI, DDDI, and SESS Intellectual disability, facial dysmorphism, scoliosis, long QT 11
Val107Phe/Arg116Trp Reduction in catalytic activity for the EEEI and SESS (V107P; ~95%, R116W; ~15%) Severe global developmental delay with postnatal growth, skeletal anomalies, truncal hypotonia with hypertonia of the extremities, minor facial features, behavioral anomalies 13
Arg83Cys Interfere Ac-CoA binding, 60% reducuction in Nt-catalytic activity Hypotonia, global developmental delay, dysmorphic features, autism spectrum disorder, epileptic encephalopathy, extrapyramidal signs, hypertension with left ventricular hypertrophy, thin corpus callosum, progressive white matter loss 16
Phe128Leu/Ile Altered structure and reduced stability, dramatic recuction of Nt-catalytic activity Moderate to severe intellectually disabled, feeding difficulties, eye anomalies, hypotonia, developmental delay 15

Additionally, a splice mutation in the intron 7 splice donor site (c.471+2T → A) of NAA10 was implicated as a cause of Lenz microphthalmia syndrome12. Developmental abnormalities, such as microphthalmia or anophthalmia, developmental delay, intellectual disability, skeletal abnormalities and malformations of teeth, fingers, and toes, were observed. Gene expression array studies in patient fibroblasts displayed the dysregulation of several genes involved in embryonic, organ, tissue and skeletal and muscular system development, and above all, these changes were associated with the retinoic acid and Wnt signaling pathways, which are necessary for normal eye development. Furthermore, TSC2 is known to be stabilized by NAA10-dependent N-terminal acetylation. C-terminal truncated mutation of NAA10 demonstrates both loss of NAA10-TSC2 binding and reduced TSC2 protein levels, thereby resulting in perturbed mTOR signaling12. Given these findings, the N-terminal acetyltransferase activity of NAA10 plays a critical role in human development.

Developmental roles in other organisms

In several species, various developmental defects have also been observed due to a deficiency of NAA10 activity (Table 2). NAA10 was first discovered in yeast, where it was found to be crucial for cell growth and sporulation. The yNaa10 deleted strain, lacking NatA activity, is viable but exhibits a wide range of defects, including slow growth, de-repression of the silent mating type locus HML (Hidden MAT Left), temperature and salt sensitivity, and failure to enter G0 phase and sporulate4,79. Recently, the yeast model of Ogden syndrome expressing hNaa10 S37P in yNaa10 deficient strains has also been shown to have impaired growth and resistance to stress and mating34,35. Naa10 is required for Arabidopsis thaliana development, and thereby, Naa10 deficient mutations induce growth retardation and are lethal36. Additionally, the loss of Naa10 in Trypanosoma brucei leads to mortality37. In Caenorhabditis elegans, daf-31 (the ortholog of NAA10) is essential for larval development, metabolism and adult lifespan. Daf-31 mutants fail to properly enter the dauer stage, which is pivotal for C. elegans survival during starvation (when nutrients are limited). Furthermore, the mutants display developmental arrest under abundant nutrition and shift their metabolism to fat accumulation38. The importance of Naa10 in normal development is also supported by a Drosophila melanogaster study in which two hypomorphic mutations of Naa10 led to pleiotropic oogenesis defects, including aberrant mitoses, defects in egg chamber encapsulation and nurse cell chromatin dispersion39. Further, Naa10 deficient mutations have been shown to affect cell survival and proliferation and cause lethality. In a recent Danio rerio study, morpholino-mediated knockdown of Naa10 resulted in increased lethality, growth retardation and abnormal development, such as a bent axis, abnormal eyes, and bent tails, indicating the importance of Naa10 in early zebrafish development and viability40.

Table 2.

Summary of NAA10 mutations in organisms

Organism scientific name Homolog Symbol of mutation Type of mutation Protein effect/ molecular mechanism Phenotype Ref.
Yeast Saccharomyces cerevisiae ARD1, yNaa10 ard1::HIS3 Inserting a Barn HI fragment containinng the HIS3 gene into the Barn HI site of plasmid YCpE18 that lies within the functional sequence of ARD1 Defect in transcription of a-specific genes, Permit expression of the information resident at HML Reduced viability, sensitive to heat shock and salt, fail to enter stationay phase, lack of glycogen accumulation, sporulation defect, poor mating, fail to undergo meiosis 8,9
nat1-5::LEU; ard1 Mating nat1 and ard1 single mutant for nat1 ard1 double mutant Impaired N-terminal activity (predicted); single mutants of nat1 (Naa15) and ard1 (Naa10) displayed identical phenotypes, no additional phenotypes are found in double mutant Inable to sporulate, slow growth, reduced mating, inhibit sporulation, impaired resistance to heat shock, fail to G1 arrest, partial depression of HML, fail to accumulate storage 4,7
y[hNatA S37P] A strain without yNatA and expression human NatA with a mutated hNaa10 S37P Lack of proper complex formation with hNaa15 and reduced in vitro catalytic activity, decreased of Nt-acetylome using COFRADIC, increase in the Hsp70 family proteins Growth defect, sensitive to caffeine and cycloheximide, Impaired resistance to heatshock, decreased mating efficiency 34,35
yS39P S39P mutation in homologous position to human Naa10 S37 No obious effects 35
Plant Arabidopsis At5g13780, AtNAA10 naa10-1 T-DNA insertion-disrupting gene expression Impaired N-terminal activity; Naa15 mutation also shared same phenotypes Growth retardation in vegetative stage, lethal, abortion of embryogenesis, drought-adapted root morphology 36
amiNaa10 Depleted-RNA silencing
Protozoan parasite Trypanosoma brucei TbARD1 Ard1 null mutant Removal of the ARD1 coding region Impaired N-terminal activity (predicted) Impaired growth in bloodstream-form cells, reduced differentiation to insect-stage cells 37
Worm Caenorhabditis elegans DAF-31 daf-31(m655) Remove 151 bp of promoter upstream of the ATG start codon and 242 bp of daf-31 coding region dowstream of the ATG start codon Regulates the transcriptional activity of DAF-16 (FOXO transcription factor) Developmental larval arrest, fat accumulation, formation of dauer-like larvae under starvation conditions, decreased lifespan, no SDS-resistant, cannot resume development and reproduction after food re-providing 38
daf-31 RNAi RNAi knock down; reducing daf-31 mRNA Decreased lifespan
daf-31 OE Overexpression; full length dar-31 genomic DNA was cloned into pGEM-T Increase lifespan in daf-2 mutant, enhancing reproduction
Fruit fly Drosophila melanogaster vnc vncBDk Frame shift mutation in acetyltransferase-truncated enzymatic region Impaired N-terminal activity (predicted) Pleiotropic oogenesis, aberrant mitosis, egg chamber encapsulation defects, nurse cell chromatin dispersion defects 39
vnc14 Copia insertion in the intron
Zebra fish Danio rerio wufc66b08, zNaa10 naa10MO Morpholino-based knockdown Predicted N-terminal activity; zNaa10 has identical substrate specificity to hNaa10 in vitro Lethality, growth retardation, bent axis and tails, abnormal eyes, less pigmentation 40

Neuronal development

During brain development in mouse, Naa10 and Naa15 (the auxiliary subunit of NatA) are highly expressed in regions rich in proliferating and migrating cells, such as the ventricular zone, neocortex, olfactory bulb, and hippocampus41. The expression of both genes is down-regulated as neurons differentiate and mitotic and migratory activities subside. Then, once again, their expression increases during postnatal development in the hippocampus and during the neuronal dendritic development of Purkinje cells (PCs) in the cerebellum. This finding indicates that the regulation of expression of both genes is related to neuronal development, especially in the hippocampus and in the PCs of the cerebellum.

The acetylation of α-tubulin has been reported to be involved in regulating microtubule (MT) stability and dynamics, neuron polarization, and neurite branching and promotes vesicular transport on MTs in differentiated neurons4246. A recent study showed that the inhibition of Naa10 or acetyltransferase activity significantly reduced the dendritic extension of cultured neurons47. Furthermore, Naa10 and Naa15 proteins co-localized with MTs in dendrites and induced the acetylation of tubulin in the brain fraction. Additionally, the dendritic arborization defect phenotype caused by the over-expression of HDAC6, a major deacetylase of α-tubulin, was rescued by the co-expression of Naa10. Therefore, the authors postulated that Naa10 counteracts HDAC6 by acetylating α-tubulin, thereby promoting MT stability for dendritic development. In spite of this fact, it is not clear that α-tubulin is the only distinct substrate of Naa10 that participates in dendritic development because the tubulin fractions contain both α/β-tubulin. Moreover, it is uncertain whether tubulin is acetylated by the N-terminal activity or lysine activity of Naa10. The lysine 40 residue of either tubulin is de-acetylated by HDAC64850, so lysine acetylation may be a potential catalytic function of α-tubulin. Characterizing the impact of whichever acetyl activity is involved in tubulin acetylation will help define a specific mechanism for neuronal development.

Melanogenesis

Naa10 knockdown in Zebra fish 2 days post-fertilization embryos showed less pigmentation, including abnormal development40. Pigmentation in organisms is due to the deposition of the pigment melanin, which is produced by specialized cells called melanocytes. In the process that produces melanin, which is called melanogenesis, the most important molecule among melanocyte-stimulating hormones (MSHs) is the proopiomelanocortin (POMC)-derived peptide α-MSH51,52. α-MSH is known to be N-terminally acetylated, and its stability and potency in stimulating pigment dispersion are increased by Nt-acetylation5356. So far, N-acetyl transferase enzyme acetylating α-MSH has not been identified yet. NatA is known to acetylate the amino acids starting with Ser, Ala, Thr, Val, Gly, and Cys28. Based on this fact, the N-terminus of α-MSH, which starts with serine, demonstrates the possibility that α-MSH could be a potential target of NatA. In the future, more studies are needed to reveal the direct regulation of α-MSH and melanogenesis by Naa10.

Spermatogenesis

NAA11 (also known as Ard1b; ARD2), a homolog of NAA10, is predominantly expressed in mouse57 and human58 testis. Naa11 can reconstitute functional NAT in the presence of Naa15, where Naa11 is functionally equivalent to Naa10. Interestingly, NAA10 and NAA11 display opposite expression patterns during spermatogenesis. In the mouse, the expression of Naa11 is upregulated during meiosis, whereas Naa10 expression is downregulated. In contrast, Naa10 is expressed in pre-meiotic spermatogonia, which do not show Naa11 expression. Therefore, Pang et al. speculated that compensation for the loss of X-linked Naa10 occurs by expressing autosomal Naa11 due to the sex chromosome inactivation during male meiosis57,59. In this sense, they also suggested that the NAT activity of Naa10 could play a pivotal role in mitotic spermatogonia and that the NAT activity of Naa11 is crucial for post-meiotic male germ cells59. Furthermore, the differential expression of NAA10 and NAA11 was shown in the human promyelocytic NB4 cell line upon differentiation21; NAA10 expression decreased with the induction of differentiation in NB4 cells, but the level of NAA11 remained unchanged, implying that Naa11 has a role in the cellular differentiation process and that Naa10 has a role in the cellular proliferation process. The differential expression pattern of Naa10/Naa11 suggests that Naa11 is complementary to Naa10 at least in the mice and that its biological role could be important in spermiogenesis or cellular processes59.

Lysine acetylation dependent functions of NAA10 during embryonic development

Naa10 is known to regulate cellular processes, and its effects are not only catalyzed through its major activity as a NAT but also through the N-ɛ-acetylation of several proteins2,3,6073. The N-ɛ-acetyl-activity of Naa10 requires auto-acetylation2,67; this requirement is similar to that of other acetyltransferases, which acetylate themselves for their catalytic and functional activities74,75. Recently, gain or loss of function studies in mice have demonstrated that Naa10 plays an important role in osteoblast differentiation and the early phases of bone formation3. Overexpression of Naa10 in mice results in the delayed closure of calvarial fontanels and reduced bone density, osteoblast surfaces and mRNA levels of the osteoblastogenic genes in calvaria. In contrast, Naa10 deficient mice display calvarial and femoral bone development to a greater extent on postnatal day 3. Mechanically, Naa10 interacts with the RUNT domain of Runt-related transcription factor 2 (Runx2), which is the master regulator of osteoblast development, and acetylates it at K225. The lysine acetylation of Runx2 restricts its transcriptional activity by interfering with CBFβ binding to Runx2. On the other hand, Runx2 stabilizes Naa10 in osteoblasts during bone morphogenic protein 2 (BMP-2)-induced differentiation through its inhibition of IKK-mediated phosphorylation and degradation of Naa10, which in turn inhibits Runx23 (Table 3).

Table 3.

Summary of NAA10 mutations in mouse

Organism scientific name Homolog Symbol of mutation Type of mutation Protein effect/ molecular mechanism Phenotype Ref.
Mouse Mus musculus Naa10 TgNaa10235 Overexpression of Naa10235; two different founders #10 and #15 were used Blocks the Runx2–CBFb interaction by acetylating Runx2 at K225 Delayed calvarial cone development 3
Naa10 KO Remove Exon1 containing the start codon and Exon2–4 containing N-acetyltransferases, NLS and the Acetyl-coA binding domain Enhance the the Runx2–CBFb interaction Facilitating calvarial bone development 3
Naa10f/Y; EIIa-Cre Insertion of loxp into the intron 1 and 6, and the Neo cassette flanked by FRT into the sixth intron before loxp; Cre removes exon 2–6 Disrupts its binding to the imprinted allele at ICRs/DMRs and Dnmt1 recruitment Partial embryonic lethality, growth retardation, brain disorders, maternal effect lethality, defective genomic imprinting 88

In addition to Runx2, the lysine acetyl-activity of Naa10 has been reported to target proteins such as β-catenin (CTNNB1)60,61, Phosphoglycerate kinase 1 (PGK1)72,73, Hypoxia inducible factor 1α (HIF-1 α)6668, Myosin light-chain kinase (MLCK)62, Androgen receptor(AR)64,65, enzyme methionine sulfoxide reductase A (MSRA)63, SAM domain and HD domain containing protein 1 (SAMHD1)69, Heat shock protein 70 (Hsp70)70, Aurora kinase A (AuA)71, and Naa10 itself2,67. The lysine acetyltransferase activity of NAA10 catalyzing these targets has not yet been directly implicated in development, but the targets are essential for developmental signaling pathways, such as Wnt/β-catenin signaling7678, autophagy7981 and the HIF-1 regulatory pathway8284. Accordingly, there is a possibility that NAA10 could influence developmental processes via these signaling pathways. On the other hand, Magin et al. reported data on the lysine acetyl-activity of NAA10, demonstrating that NAA10 does not acetylate the lysine residues of MLCK, MSRA, or RUNX285. For the lysine acetyl-activity of NAA10, earlier reports demonstrated that the auto-acetylation of NAA10 at K136 was a critical step to generate an active form. For example, NAA10 K136R, a mutation in the auto-acetylation site, failed to acetylate β-catenin and did not succeed in the recruitment of β-catenin on the cyclin D1 promoter2. Therefore, the inability of NAA10 to acetylate the lysine residues of MLCK, MSRA and RUNX2 could be due to non-auto acetylated NAA10. There is a possibility that Magin et al. performed their assay with non-auto acetylated NAA10, thus losing lysine acetyl-activity in vitro. Nevertheless, more research is required to understand the role of lysine acetylation by Naa10.

Acetylation independent functions of NAA10 during embryonic development

Several recent studies have suggested that NAA10 is able to interact directly with other proteins and enhance or inhibit the activity of its partner in an acetylation-independent manner86. The signaling pathways of NAA10 and its binding partners have been actively investigated for cell growth and function in cancer research, but reports on acetylation-independent roles of NAA10 during development are very partial as described below.

Genomic imprinting regulation in embryonic development

Genomic imprinting is an epigenetic process controlled by DNA methylation, and it plays a vital role in normal development. During embryonic development, the establishment of appropriate imprinting is accomplished by the intact regulation of Dnmt3 and Dnmt1 DNA methyltransferases87. Lee et al. reported that Naa10 deficiency mice exhibited developmental defects, including partial embryonic lethality, postnatal growth retardation, brain disorders, and maternal effect lethality, resembling the phenotypes caused by the dysregulation of genomic imprinting88 (Table 3). The authors described that despite questions about how Naa10 selectively binds to the imprinted allele, mechanistically, Naa10 binds to the unmethylated GCXGXG in the imprinting control region (ICR)/differentially methylated region (DMR) of the imprinted allele and then recruits Dnmt1 for methylation in the S phase. In addition, by showing the disrupted DNA binding activity of clinical NAA10 mutations (S37P, V107F, and R116W) to ICR, a potential connection between NAA10 mutation-associated syndromes and defects in DNA methylation and genomic imprinting was presented. Together, these results suggested that normal DNA methylation and genomic imprinting is regulated by appropriate ICR binding of Naa10 and DNMT1 recruitment during development. Previously, Lee et al. demonstrated that Naa10 acetyl activity does not mediate Naa10-DNMT1 binding and does not stimulate the activity of DNMT189. However, even though Naa10 acetyl activity is dispensable for stimulating DNMT1 activity, we could obtain an insight from their recent study that showed that the N-terminal acetyl-activity of Naa10 is required for binding to ICRs/DMRs. The authors showed that reduced DNA binding to clinically relevant mutations (S37P; defects in Naa15 binding domain for NatA complex, V107F; mutation in the acetyltransferase domain, R116W; putative interference with Ac-CoA binding15) are associated with N-terminal acetyltransferase activity, which is not related to the DNA-binding domain at the C terminus of Naa109. Given these results, there is a possibility that the enzyme activity of Naa10 directly or indirectly influences ICR binding. For example, Naa10 may combine with other proteins to acetylate the N-terminal residue, and then, these proteins may interact with ICRs/DMRs together. Interestingly, unlike other reports in other species, including humans, Naa10 deficient mice exhibited only a few phenotypes, such as embryonic lethality and growth retardation88. Moreover, some of the Naa10 deficient mice developed to term. The authors suggested some reasons for the decreased penetrance of various phenotypes. First, they suggested that this finding was a general effect of imprinting disorders caused by the deficiency of genes that maintain genomic imprinting during global DNA demethylation in zygotes. Second, the remaining DNA methylation occurred at different regions in each individual mouse, which may contribute to stochastic phenotypes. Third, the dysregulation of other imprinted genes, such as Igf2, Ascl2, and Grb10, and the effects of unidentified non-imprinted genes or protein acetylation by Naa10 deficiency are suggested. In spite of these descriptions, there are still issues to be resolved. It would have been a more complete study if the maternal effects leading to the death of embryos and neonatal mice were explained and if a histological analysis in not only placenta but also whole embryos was performed to determine the precise effects of embryonic lethality. Therefore, more elaborate mechanisms remain to be determined and more extensive mouse studies are needed.

Vasculogenesis

Xu et al. demonstrate a potential role of Naa10 in vasculogenesis and neurogenesis through the regulation of UNC-5 Homolog B (UNC5B) and Netrin-1 (NTA1)90. UNC5B and its ligand NTA1 function as essential genes in morphogenesis of the vascular system or nervous system and the negative regulation of Naa10. Knockdown of Naa10 induced morphological changes (shuttle-shaped membrane protrusion) and increased the ability for tube formation in both H1299 lung cancer cell lines and immortalized mouse endothelial cell lines. Additionally, the expression of UNC5B and NTA1 increased in Naa10 knockdown H1299 cells, and negative regulation was also verified in the mouse caudal half region of E10 embryos (when exuberant vasculature developed at that stage)90. However, a direct mechanism explaining how Naa10 regulates NTA1 and its receptor UNC5B has not been determined. Nevertheless, it has been reported that Naa10 physically binds with RelA/p65, an NFκB transcription factor and a negative regulator of NTA191,92. Therefore, the authors speculate that Naa10 physically interacts with p65, thereby negatively regulating NTA1 and its receptor UNC5B.

Conclusion and perspectives

In this review, we summarized the functions of NAA10 that are enzyme activity-dependent and -independent during the development of several organisms. Most studies have focused on the N-terminal activity of NAA10, whereas some findings have been related to lysine activity and the independent role of NAA10. Our overall understanding of the function of NAA10 in developmental processes suggests the following insights. First, depending on which acetyl-activity is acting and how it affects development, the corresponding physiological responses could be very different. NatA is presumed to act on a large number of substrates involved in a multitude of different cellular processes. As NatA targets many substrates, it could be expected to affect diverse cellular processes and eventually lead to developmental processes in many different organs. On the other hand, since the known targets of lysine acetylation by NAA10 mediate important signaling pathways during development, more intensive and accurate mechanistic studies of these signaling pathways could reveal the role of NAA10 in development. It is also important to understand how the regulation of NAA10 itself is managed during the developmental stage. For example, NAA10 auto-acetylation activates its lysine catalytic activity, and active IKKβ degrades NAA10 by phosphorylation91. Furthermore, NAA10 acts as a coactivator of DNMT1 without its enzymatic activity. Likewise, given that NAA10 carries out a wide spectrum of functions, the cellular-, tissue- and developmental stage-specific effects of NAA10 need to be discovered. Second, interestingly, some individuals normally survive and grow with decreased or mutated NAA10, which suggests the possibility of a homologous gene that might compensate for the function of NAA10. This suggestion is supported by the existence of NAA11, which has been identified as a homologous gene of NAA10, and the reciprocal expression between NAA10 and NAA11 during spermatogenesis. However, we are unable to answer whether NAA11, whose expression appears to be limited to the testis, can cover the entire function of the ubiquitously expressed NAA10 protein. Therefore, an open question about the existence of another homologous gene to NAA10 in different tissues remains. The goal of future studies will be to elaborate on the cellular/molecular specific activity and distinct pathways of NAA10. Above all, in vivo studies are necessary to analyze the definite biological effects of NAA10.

Acknowledgements

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government (NRF-2012R1A3A2026454, NRF-2012R1A6A3A04040206, NRF-2015M3A9B6029138, and NRF-2017R1D1A1B03032286).

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Mi-Ni Lee, Hyae Yon Kweon

References

  • 1.Park EC, Szostak JW. ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity. EMBO J. 1992;11:2087–2093. doi: 10.1002/j.1460-2075.1992.tb05267.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Seo JH, et al. Arrest defective 1 autoacetylation is a critical step in its ability to stimulate cancer cell proliferation. Cancer Res. 2010;70:4422–4432. doi: 10.1158/0008-5472.CAN-09-3258. [DOI] [PubMed] [Google Scholar]
  • 3.Yoon H, et al. NAA10 controls osteoblast differentiation and bone formation as a feedback regulator of Runx2. Nat. Commun. 2014;5:5176. doi: 10.1038/ncomms6176. [DOI] [PubMed] [Google Scholar]
  • 4.Mullen JR, et al. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J. 1989;8:2067–2075. doi: 10.1002/j.1460-2075.1989.tb03615.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kuo HP, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci. Signal. 2010;3:ra9. doi: 10.1126/scisignal.2000590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Eiyama A, Okamoto K. Protein N-terminal acetylation by the NatA complex is critical for selective mitochondrial degradation. J. Biol. Chem. 2015;290:25034–25044. doi: 10.1074/jbc.M115.677468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lee FJ, Lin LW, Smith JA. N alpha acetylation is required for normal growth and mating of Saccharomyces cerevisiae. J. Bacteriol. 1989;171:5795–5802. doi: 10.1128/jb.171.11.5795-5802.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Whiteway M, Freedman R, Van Arsdell S, Szostak JW, Thorner J. The yeast ARD1 gene product is required for repression of cryptic mating-type information at the HML locus. Mol. Cell. Biol. 1987;7:3713–3722. doi: 10.1128/mcb.7.10.3713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Whiteway M, Szostak JW. The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell. 1985;43(2 Pt 1):483–492. doi: 10.1016/0092-8674(85)90178-3. [DOI] [PubMed] [Google Scholar]
  • 10.Dorfel MJ, Lyon GJ. The biological functions of Naa10 - from amino-terminal acetylation to human disease. Gene. 2015;567:103–131. doi: 10.1016/j.gene.2015.04.085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Casey JP, et al. NAA10 mutation causing a novel intellectual disability syndrome with Long QT due to N-terminal acetyltransferase impairment. Sci. Rep. 2015;5:16022. doi: 10.1038/srep16022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Esmailpour T, et al. A splice donor mutation in NAA10 results in the dysregulation of the retinoic acid signalling pathway and causes Lenz microphthalmia syndrome. J. Med. Genet. 2014;51:185–196. doi: 10.1136/jmedgenet-2013-101660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Popp B, et al. De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females. Eur. J. Hum. Genet. 2015;23:602–609. doi: 10.1038/ejhg.2014.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rope AF, et al. Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am. J. Hum. Genet. 2011;89:28–43. doi: 10.1016/j.ajhg.2011.05.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Saunier C, et al. Expanding the phenotype associated with NAA10-related N-terminal acetylation deficiency. Hum. Mutat. 2016;37:755–764. doi: 10.1002/humu.23001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sidhu M, Brady L, Tarnopolsky M, Ronen GM. Clinical manifestations associated with the N-terminal-acetyltransferase NAA10 gene mutation in a girl: ogden syndrome. Pediatr. Neurol. 2017;76:82–85. doi: 10.1016/j.pediatrneurol.2017.07.010. [DOI] [PubMed] [Google Scholar]
  • 17.Tribioli C, et al. Isolation of new genes in distal Xq28: transcriptional map and identification of a human homologue of the ARD1 N-acetyl transferase of Saccharomyces cerevisiae. Hum. Mol. Genet. 1994;3:1061–1067. doi: 10.1093/hmg/3.7.1061. [DOI] [PubMed] [Google Scholar]
  • 18.Chun KH, et al. Differential regulation of splicing, localization and stability of mammalian ARD1235 and ARD1225 isoforms. Biochem. Biophys. Res. Commun. 2007;353:18–25. doi: 10.1016/j.bbrc.2006.11.131. [DOI] [PubMed] [Google Scholar]
  • 19.Kim SH, et al. Characterization of ARD1 variants in mammalian cells. Biochem. Biophys. Res. Commun. 2006;340:422–427. doi: 10.1016/j.bbrc.2005.12.018. [DOI] [PubMed] [Google Scholar]
  • 20.Seo JH, Park JH, Lee EJ, Kim KW. Different subcellular localizations and functions of human ARD1 variants. Int. J. Oncol. 2015;46:701–707. doi: 10.3892/ijo.2014.2770. [DOI] [PubMed] [Google Scholar]
  • 21.Arnesen T, et al. Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. BMC Biochem. 2006;7:13. doi: 10.1186/1471-2091-7-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Xue L, et al. Global expression profiling reveals genetic programs underlying the developmental divergence between mouse and human embryogenesis. BMC Genomics. 2013;14:568. doi: 10.1186/1471-2164-14-568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yi H, et al. Gene expression atlas for human embryogenesis. FASEB J. 2010;24:3341–3350. doi: 10.1096/fj.10-158782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Noguchi S, et al. FANTOM5 CAGE profiles of human and mouse samples. Sci. Data. 2017;4:170112. doi: 10.1038/sdata.2017.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Consortium F, et al. A promoter-level mammalian expression atlas. Nature. 2014;507:462–470. doi: 10.1038/nature13182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Andersson R, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507:455–461. doi: 10.1038/nature12787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yu NY, et al. Complementing tissue characterization by integrating transcriptome profiling from the Human Protein Atlas and from the FANTOM5 consortium. Nucleic Acids Res. 2015;43:6787–6798. doi: 10.1093/nar/gkv608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Arnesen T. Towards a functional understanding of protein N-terminal acetylation. PLoS Biol. 2011;9:e1001074. doi: 10.1371/journal.pbio.1001074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Aksnes H, Hole K, Arnesen T. Molecular, cellular, and physiological significance of N-terminal acetylation. Int Rev. Cell Mol. Biol. 2015;316:267–305. doi: 10.1016/bs.ircmb.2015.01.001. [DOI] [PubMed] [Google Scholar]
  • 30.Arnesen T, et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc. Natl Acad. Sci. USA. 2009;106:8157–8162. doi: 10.1073/pnas.0901931106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Driessen HP, de Jong WW, Tesser GI, Bloemendal H. The mechanism of N-terminal acetylation of proteins. CRC Crit. Rev. Biochem. 1985;18:281–325. doi: 10.3109/10409238509086784. [DOI] [PubMed] [Google Scholar]
  • 32.Myklebust LM, et al. Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects. Hum. Mol. Genet. 2015;24:1956–1976. doi: 10.1093/hmg/ddu611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Myklebust LM, Stove SI, Arnesen T. Naa10 in development and disease. Oncotarget. 2015;6:34041–34042. doi: 10.18632/oncotarget.5867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Van Damme P, Stove SI, Glomnes N, Gevaert K, Arnesen T. A Saccharomyces cerevisiae model reveals in vivo functional impairment of the Ogden syndrome N-terminal acetyltransferase NAA10 Ser37Pro mutant. Mol. Cell. Proteom. 2014;13:2031–2041. doi: 10.1074/mcp.M113.035402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Dorfel MJ, et al. Proteomic and genomic characterization of a yeast model for Ogden syndrome. Yeast. 2017;34:19–37. doi: 10.1002/yea.3211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Linster E, et al. Downregulation of N-terminal acetylation triggers ABA-mediated drought responses in Arabidopsis. Nat. Commun. 2015;6:7640. doi: 10.1038/ncomms8640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ingram AK, Cross GA, Horn D. Genetic manipulation indicates that ARD1 is an essential N(alpha)-acetyltransferase in Trypanosoma brucei. Mol. Biochem. Parasitol. 2000;111:309–317. doi: 10.1016/s0166-6851(00)00322-4. [DOI] [PubMed] [Google Scholar]
  • 38.Chen D, et al. daf-31 encodes the catalytic subunit of N alpha-acetyltransferase that regulates Caenorhabditis elegans development, metabolism and adult lifespan. PLoS Genet. 2014;10:e1004699. doi: 10.1371/journal.pgen.1004699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wang Y, et al. Drosophila variable nurse cells encodes arrest defective 1 (ARD1), the catalytic subunit of the major N-terminal acetyltransferase complex. Dev. Dyn. 2010;239:2813–2827. doi: 10.1002/dvdy.22418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ree R, et al. The N-terminal acetyltransferase Naa10 is essential for zebrafish development. Biosci. Rep. 2015;35:e00249. doi: 10.1042/BSR20150168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Sugiura N, Adams SM, Corriveau RA. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J. Biol. Chem. 2003;278:40113–40120. doi: 10.1074/jbc.M301218200. [DOI] [PubMed] [Google Scholar]
  • 42.Li W, et al. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J. Neurosci. 2007;27:2606–2616. doi: 10.1523/JNEUROSCI.4181-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell. 2003;11:437–444. doi: 10.1016/s1097-2765(03)00038-8. [DOI] [PubMed] [Google Scholar]
  • 44.Ohkawa N, Fujitani K, Tokunaga E, Furuya S, Inokuchi K. The microtubule destabilizer stathmin mediates the development of dendritic arbors in neuronal cells. J. Cell Sci. 2007;120(Pt 8):1447–1456. doi: 10.1242/jcs.001461. [DOI] [PubMed] [Google Scholar]
  • 45.Vaillant AR, et al. Signaling mechanisms underlying reversible, activity-dependent dendrite formation. Neuron. 2002;34:985–998. doi: 10.1016/s0896-6273(02)00717-1. [DOI] [PubMed] [Google Scholar]
  • 46.MacRae TH. Tubulin post-translational modifications--enzymes and their mechanisms of action. Eur. J. Biochem. 1997;244:265–278. doi: 10.1111/j.1432-1033.1997.00265.x. [DOI] [PubMed] [Google Scholar]
  • 47.Ohkawa N, et al. N-acetyltransferase ARD1-NAT1 regulates neuronal dendritic development. Genes Cells. 2008;13:1171–1183. doi: 10.1111/j.1365-2443.2008.01235.x. [DOI] [PubMed] [Google Scholar]
  • 48.Hubbert C, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417:455–458. doi: 10.1038/417455a. [DOI] [PubMed] [Google Scholar]
  • 49.Matsuyama A, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002;21:6820–6831. doi: 10.1093/emboj/cdf682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Zhang Y, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003;22:1168–1179. doi: 10.1093/emboj/cdg115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Pritchard LE, et al. Proopiomelanocortin-derived peptides in rat cerebrospinal fluid and hypothalamic extracts: evidence that secretion is regulated with respect to energy balance. Endocrinology. 2003;144:760–766. doi: 10.1210/en.2002-220866. [DOI] [PubMed] [Google Scholar]
  • 52.Geschwind II, Huseby RA, Nishioka R. The effect of melanocyte-stimulating hormone on coat color in the mouse. Recent Prog. Horm. Res. 1972;28:91–130. [PubMed] [Google Scholar]
  • 53.O’Donohue TL, Handelmann GE, Chaconas T, Miller RL, Jacobowitz DM. Evidence that N-acetylation regulates the behavioral activity of alpha-MSH in the rat and human central nervous system. Peptides. 1981;2:333–344. doi: 10.1016/s0196-9781(81)80126-x. [DOI] [PubMed] [Google Scholar]
  • 54.Glembotski CC. Acetylation of alpha-melanotropin and beta-endorphin in the rat intermediate pituitary. Subcellular localization. J. Biol. Chem. 1982;257:10493–10500. [PubMed] [Google Scholar]
  • 55.O’Donohye TL, Handelmann GE, Miller RL, Jacobowitz DM. N-acetylation regulates the behavioral activity of alpha-melanotropin in a multineurotransmitter neuron. Science. 1982;215:1125–1127. doi: 10.1126/science.7063845. [DOI] [PubMed] [Google Scholar]
  • 56.Wilkinson CW. Roles of acetylation and other post-translational modifications in melanocortin function and interactions with endorphins. Peptides. 2006;27:453–471. doi: 10.1016/j.peptides.2005.05.029. [DOI] [PubMed] [Google Scholar]
  • 57.Pang AL, et al. Characterization, and expression analysis of the novel acetyltransferase retrogene Ard1b in the mouse. Biol. Reprod. 2009;81:302–309. doi: 10.1095/biolreprod.108.073221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Pang AL, Clark J, Chan WY, Rennert OM. Expression of human NAA11 (ARD1B) gene is tissue-specific and is regulated by DNA methylation. Epigenetics. 2011;6:1391–1399. doi: 10.4161/epi.6.11.18125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Pang A, Rennert O. Protein acetylation and spermatogenesis. Reprod. Syst. Sex Disord. Suppl 1: 5 (2013). [DOI] [PMC free article] [PubMed]
  • 60.Lim JH, Chun YS, Park JW. Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin. Cancer Res. 2008;68:5177–5184. doi: 10.1158/0008-5472.CAN-07-6234. [DOI] [PubMed] [Google Scholar]
  • 61.Lim JH, Park JW, Chun YS. Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res. 2006;66:10677–10682. doi: 10.1158/0008-5472.CAN-06-3171. [DOI] [PubMed] [Google Scholar]
  • 62.Shin DH, Chun YS, Lee KH, Shin HW, Park JW. Arrest defective-1 controls tumor cell behavior by acetylating myosin light chain kinase. PLoS One. 2009;4:e7451. doi: 10.1371/journal.pone.0007451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Shin SH, et al. Arrest defective 1 regulates the oxidative stress response in human cells and mice by acetylating methionine sulfoxide reductase A. Cell Death Dis. 2014;5:e1490. doi: 10.1038/cddis.2014.456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Wang Z, et al. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis. Proc. Natl Acad. Sci. USA. 2012;109:3053–3058. doi: 10.1073/pnas.1113356109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.DePaolo JS, et al. Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis. Oncotarget. 2016;7:71417–71428. doi: 10.18632/oncotarget.12163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Lee MN, et al. Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis. J. Natl Cancer Inst. 2010;102:426–442. doi: 10.1093/jnci/djq026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Seo JH, et al. Autoacetylation regulates differentially the roles of ARD1 variants in tumorigenesis. Int J. Oncol. 2015;46:99–106. doi: 10.3892/ijo.2014.2708. [DOI] [PubMed] [Google Scholar]
  • 68.Jeong JW, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002;111:709–720. doi: 10.1016/s0092-8674(02)01085-1. [DOI] [PubMed] [Google Scholar]
  • 69.Lee EJ, et al. SAMHD1 acetylation enhances its deoxynucleotide triphosphohydrolase activity and promotes cancer cell proliferation. Oncotarget. 2017;8:68517–68529. doi: 10.18632/oncotarget.19704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Seo JH, et al. ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation. Nat. Commun. 2016;7:12882. doi: 10.1038/ncomms12882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Vo TTL, et al. ARD1-mediated aurora kinase A acetylation promotes cell proliferation and migration. Oncotarget. 2017;8:57216–57230. doi: 10.18632/oncotarget.19332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Qian X, et al. Phosphoglycerate kinase 1 phosphorylates beclin1 to induce autophagy. Mol. Cell. 2017;65:917–931 e6. doi: 10.1016/j.molcel.2017.01.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Qian X, Li X, Lu Z. Protein kinase activity of the glycolytic enzyme PGK1 regulates autophagy to promote tumorigenesis. Autophagy. 2017;13:1246–1247. doi: 10.1080/15548627.2017.1313945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Santos-Rosa H, Valls E, Kouzarides T, Martinez-Balbas M. Mechanisms of P/CAF auto-acetylation. Nucleic Acids Res. 2003;31:4285–4292. doi: 10.1093/nar/gkg655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Mellert HS, McMahon SB. Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells. Trends Biochem. Sci. 2009;34:571–578. doi: 10.1016/j.tibs.2009.06.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Basson MA. Signaling in cell differentiation and morphogenesis. Cold Spring Harb. Perspect. Biol. 2012;4:a008151. doi: 10.1101/cshperspect.a008151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell. 2009;17:9–26. doi: 10.1016/j.devcel.2009.06.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–480. doi: 10.1016/j.cell.2006.10.018. [DOI] [PubMed] [Google Scholar]
  • 79.Mizushima N. Autophagy: process and function. Genes Dev. 2007;21:2861–2873. doi: 10.1101/gad.1599207. [DOI] [PubMed] [Google Scholar]
  • 80.Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. Dev. Cell. 2008;15:344–357. doi: 10.1016/j.devcel.2008.08.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl Acad. Sci. USA. 2003;100:15077–15082. doi: 10.1073/pnas.2436255100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Tomita S, et al. Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol. Cell Biol. 2003;23:6739–6749. doi: 10.1128/MCB.23.19.6739-6749.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Iyer NV, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12:149–162. doi: 10.1101/gad.12.2.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 2003;54:17–28. doi: 10.1146/annurev.med.54.101601.152418. [DOI] [PubMed] [Google Scholar]
  • 85.Magin RS, March ZM, Marmorstein R. The N-terminal acetyltransferase Naa10/ARD1 does not acetylate lysine residues. J. Biol. Chem. 2016;291:5270–5277. doi: 10.1074/jbc.M115.709428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Hollebeke J, Van Damme P, Gevaert K. N-Terminal acetylation and other functions of Nα-acetyltransferases. Biol. Chem. 2012;393:291–298. doi: 10.1515/hsz-2011-0228. [DOI] [PubMed] [Google Scholar]
  • 87.Barlow DP, Bartolomei MS. Genomic imprinting in mammals. Cold Spring Harb. Perspect. Biol. 2014;6:a018382. doi: 10.1101/cshperspect.a018382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Lee CC, et al. The Role of N-alpha-acetyltransferase 10 protein in DNA methylation and genomic imprinting. Mol. Cell. 2017;68:89–103 e7. doi: 10.1016/j.molcel.2017.08.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Lee CF, et al. hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing. J. Clin. Invest. 2010;120:2920–2930. doi: 10.1172/JCI42275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Xu H, Han Y, Liu B, Li R. Unc-5 homolog B (UNC5B) is one of the key downstream targets of N-alpha-Acetyltransferase 10 (Naa10) Sci. Rep. 2016;6:38508. doi: 10.1038/srep38508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Xu H, et al. N-alpha-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression. Carcinogenesis. 2012;33:1193–1202. doi: 10.1093/carcin/bgs144. [DOI] [PubMed] [Google Scholar]
  • 92.Mirakaj V, et al. Netrin-1 dampens pulmonary inflammation during acute lung injury. Am. J. Respir. Crit. Care Med. 2010;181:815–824. doi: 10.1164/rccm.200905-0717OC. [DOI] [PubMed] [Google Scholar]

Articles from Experimental & Molecular Medicine are provided here courtesy of Korean Society for Biochemistry and Molecular Biology

RESOURCES